What question did this study set out to answer?

To examine systemic health risks associated with intra-pancreatic fat deposition and identify a quantitative radiological threshold for clinical risk stratification.

February 19, 2026Insights into ImagingOpen Access

Intra-pancreatic fat deposition links to widespread systemic health risks: UK Biobank prospective cohort study

Q: What are the key findings of this study?

Higher intra-pancreatic fat deposition increased risk of 12 multi-system diseases with hazard ratios ranging from 1.11 to 1.28, notably HR 1.27 for non-insulin-dependent diabetes over median 6.27 years.

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: General population with measurement of intra-pancreatic fat deposition (n=25547). Intervention: Higher intra-pancreatic fat deposition (IPFD) vs. Lower intra-pancreatic fat deposition. Primary outcome: Incident multi-system diseases associated with intra-pancreatic fat deposition (HR 1.27 for non-insulin-dependent diabetes (95% CI 1.16–1.40), HR 1.14 for primary hypertension (95% CI 1.07–1.21), HR 1.21 for heart failure (95% CI 1.08–1.36), HR 1.21 for cerebral infarction (95% CI 1.05–1.40), HR 1.22 for cholelithiasis (95% CI 1.08–1.37), HR 1.13 for gastritis and duodenitis (95% CI 1.05–1.23), HR 1.18 for diaphragmatic hernia (95% CI 1.08–1.28), HR 1.17 for chronic renal failure (95% CI 1.05–1.29), HR 1.18 for gonarthrosis (95% CI 1.07–1.29), HR 1.20 for disorders of refraction and accommodation (95% CI 1.10–1.30), HR 1.11 for senile cataract (95% CI 1.05–1.19), HR 1.28 for sleep disorders (95% CI 1.08–1.51), p=All FDR corrected p-values < 0.05 except cerebral infarction (FDR=0.041) and sleep disorders (FDR=0.025)).

View Full Paper

Ask AI

Bookmark

Key result

Higher intra-pancreatic fat deposition linked to up to ~28% greater risk across 12 multi-system diseases.

HR 1.27 for non-insulin-dependent diabetes (95% CI 1.16–1.40), HR 1.14 for primary hypertension (95% CI 1.07–1.21), HR 1.21 for heart failure (95% CI 1.08–1.36), HR 1.21 for cerebral infarction (95% CI 1.05–1.40), HR 1.22 for cholelithiasis (95% CI 1.08–1.37), HR 1.13 for gastritis and duodenitis (95% CI 1.05–1.23), HR 1.18 for diaphragmatic hernia (95% CI 1.08–1.28), HR 1.17 for chronic renal failure (95% CI 1.05–1.29), HR 1.18 for gonarthrosis (95% CI 1.07–1.29), HR 1.20 for disorders of refraction and accommodation (95% CI 1.10–1.30), HR 1.11 for senile cataract (95% CI 1.05–1.19), HR 1.28 for sleep disorders (95% CI 1.08–1.51)
P All FDR corrected p-values < 0.05 except cerebral infarction (FDR=0.041) and sleep disorders (FDR=0.025)
n=25,547

Why the study?

Intra-pancreatic fat deposition is known to be associated with pancreatic diseases, but its systemic implications remain unclear.

Does intra-pancreatic fat deposition increase the risk of multi-systemic diseases in adults?

Key Points

To examine systemic health risks associated with intra-pancreatic fat deposition and identify a quantitative radiological threshold for clinical risk stratification.
Prospective cohort analysis of 25,547 UK Biobank participants evaluated with MRI-derived pancreatic proton density fat fraction over a median follow-up of 6.27 years.
Multivariable Cox proportional hazards models, causal mediation, and restricted cubic splines evaluated IPFD-disease associations, alongside bidirectional Mendelian randomization using UK Biobank and FinnGen cohorts.
Higher IPFD independently elevated risks for 12 diseases, including non-insulin-dependent diabetes (HR 1.27, 95% CI: 1.16–1.40, FDR < 0.001), heart failure (HR 1.21, 95% CI: 1.08–1.36, FDR = 0.009), and sleep disorders (HR 1.28, 95% CI: 1.08–1.51, FDR = 0.025).
Causal mediation by non-insulin-dependent diabetes was negligible across diseases (proportion mediated < 2%, p > 0.05), while Mendelian randomization supported potential causal roles for IPFD in gonarthrosis and ocular disorders.
Receiver operating characteristic analysis identified an optimal IPFD threshold of 7.35% (95% CI: 5.68–9.23%) for multi-system disease risk stratification.

Study Design

Type

Cohort (n=25,547)

Multicenter

Yes

Structured PICO

Does intra-pancreatic fat deposition increase the risk of multi-systemic diseases in adults?

Population

25,547 UK Biobank participants, median age 64.00, 51% female, 93% white. Key inclusion: underwent abdominal MRI with quantifiable intra-pancreatic fat deposition (IPFD) measurements.

Intervention

Higher intra-pancreatic fat deposition (IPFD) assessed by MRI-derived pancreatic proton density fat fraction

Comparator

Lower intra-pancreatic fat deposition (e.g., lowest quartile)

Outcome

First occurrence of 12 multi-systemic diseases (non-insulin-dependent diabetes, primary hypertension, heart failure, cerebral infarction, cholelithiasis, gastritis and duodenitis, diaphragmatic hernia, chronic renal failure, gonarthrosis, disorders of refraction and accommodation, senile cataract, and sleep disorders)hard clinical

Main Result

Effect estimate: HR 1.27 for non-insulin-dependent diabetes (95% CI 1.16–1.40), HR 1.14 for primary hypertension (95% CI 1.07–1.21), HR 1.21 for heart failure (95% CI 1.08–1.36), HR 1.21 for cerebral infarction (95% CI 1.05–1.40), HR 1.22 for cholelithiasis (95% CI 1.08–1.37), HR 1.13 for gastritis and duodenitis (95% CI 1.05–1.23), HR 1.18 for diaphragmatic hernia (95% CI 1.08–1.28), HR 1.17 for chronic renal failure (95% CI 1.05–1.29), HR 1.18 for gonarthrosis (95% CI 1.07–1.29), HR 1.20 for disorders of refraction and accommodation (95% CI 1.10–1.30), HR 1.11 for senile cataract (95% CI 1.05–1.19), HR 1.28 for sleep disorders (95% CI 1.08–1.51)

p-value: p=All FDR corrected p-values < 0.05 except cerebral infarction (FDR=0.041) and sleep disorders (FDR=0.025)

Intra-pancreatic fat deposition is an independent risk factor for multiple systemic diseases, including cardiovascular and metabolic conditions, with a threshold of 7.35% potentially useful for clinical screening.

Limitations

Study population predominantly European, limiting generalizability to other ethnicities
Mendelian randomization assumptions may not fully apply for complex pathophysiology
Underdiagnosis of diseases may introduce reverse causation bias
IPFD cut-off requires external validation
Potential surveillance bias due to differential healthcare utilization

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

IPFD may enhance multi-system disease risk stratification; leaves open causality and therapeutic targeting in observational data.

Cite This Study

Cai et al. (2026) conducted a cohort in General population with measurement of intra-pancreatic fat deposition (n=25,547). Higher intra-pancreatic fat deposition (IPFD) vs. Lower intra-pancreatic fat deposition was evaluated on Incident multi-system diseases associated with intra-pancreatic fat deposition (HR 1.27 for non-insulin-dependent diabetes (95% CI 1.16–1.40), HR 1.14 for primary hypertension (95% CI 1.07–1.21), HR 1.21 for heart failure (95% CI 1.08–1.36), HR 1.21 for cerebral infarction (95% CI 1.05–1.40), HR 1.22 for cholelithiasis (95% CI 1.08–1.37), HR 1.13 for gastritis and duodenitis (95% CI 1.05–1.23), HR 1.18 for diaphragmatic hernia (95% CI 1.08–1.28), HR 1.17 for chronic renal failure (95% CI 1.05–1.29), HR 1.18 for gonarthrosis (95% CI 1.07–1.29), HR 1.20 for disorders of refraction and accommodation (95% CI 1.10–1.30), HR 1.11 for senile cataract (95% CI 1.05–1.19), HR 1.28 for sleep disorders (95% CI 1.08–1.51), p=All FDR corrected p-values < 0.05 except cerebral infarction (FDR=0.041) and sleep disorders (FDR=0.025)). Higher intra-pancreatic fat deposition increased risk of 12 multi-system diseases with hazard ratios ranging from 1.11 to 1.28, notably HR 1.27 for non-insulin-dependent diabetes over median 6.27 years.

synapsesocial.com/papers/6996a77aecb39a600b3ed24f https://doi.org/10.1186/s13244-026-02206-7

View Full Paper

Ask AI

Bookmark

Intra-pancreatic fat deposition links to widespread systemic health risks: UK Biobank prospective cohort study

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Intra-pancreatic fat deposition links to widespread systemic health risks: UK Biobank prospective cohort study

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider